Under these conditions, detection of HIF1α in plasma circulating sEVs was feasible by Western blotting and correlated with clinical recurrence in all luminal breast cancer patients examined (Figure 10, E and F), up to 103 months after initial diagnosis (Figure 10G). The gene discussed is HIF1A; the disease is breast carcinoma.